GW Pharmaceuticals PLC GW Added to NASDAQ Biotechnology Index (4080A)
December 22 2014 - 1:00AM
UK Regulatory
TIDMGWP
RNS Number : 4080A
GW Pharmaceuticals PLC
22 December 2014
GW Pharmaceuticals Added to NASDAQ Biotechnology Index
London, UK, 22 December 2014: GW Pharmaceuticals plc (NASDAQ:
GWPH, AIM: GWP, GW, the Company or the Group), a biopharmaceutical
company focused on discovering, developing and commercializing
novel therapeutics from its proprietary cannabinoid product
platform, today announced that it has been selected for addition to
the NASDAQ Biotechnology Index(R) (Nasdaq:NBI), which will become
effective at the open of U.S. markets today.
The NASDAQ Biotechnology Index is designed to track the
performance of a set of NASDAQ listed securities that are
classified as either biotechnology or pharmaceutical according to
the Industry Classification Benchmark (ICB). The NASDAQ
Biotechnology Index is re-ranked semi-annually in May and November.
The NASDAQ Biotechnology Index is the basis for the iShares Nasdaq
Biotechnology Index(SM) Fund (Nasdaq:IBB), which seeks investment
results that correspond generally to the price and yield
performance, before fees and expenses, of the NASDAQ Biotechnology
Index. In addition, options based on the NASDAQ Biotechnology Index
and the iShares NASDAQ Biotechnology Index Fund trade on various
exchanges. For more information about the NASDAQ Biotechnology
Index, including eligibility criteria, visit www.nasdaq.com.
About GW Pharmaceuticals plc
Founded in 1998, GW is a biopharmaceutical company focused on
discovering, developing and commercializing novel therapeutics from
its proprietary cannabinoid product platform in a broad range of
disease areas. GW commercialized the world's first plant-derived
cannabinoid prescription drug, Sativex(R), which is approved for
the treatment of spasticity due to multiple sclerosis in 27
countries outside the United States. Sativex is also in Phase 3
clinical development as a potential treatment of pain associated
with advanced cancer. This Phase 3 program is intended to support
the submission of a New Drug Application for Sativex in cancer pain
with the U.S. Food and Drug Administration and in other markets
around the world. GW is also advancing an orphan drug program in
the field of childhood epilepsy with a focus on Epidiolex(R), which
is in Phase 2/3 clinical development for the treatment of Dravet
syndrome and which is also expected to enter Phase 3 clinical
trials in the treatment of Lennox-Gastaut syndrome.GW has a deep
pipeline of additional cannabinoid product candidates which
includes compounds in Phase 1 and 2 clinical development for
glioma, ulcerative colitis, type 2 diabetes, and schizophrenia. For
further information, please visit www.gwpharm.com.
Forward-looking statements
This news release contains forward-looking statements that
reflect GW's current expectations regarding future events,
including statements regarding financial performance, the timing of
clinical trials, the relevance of GW products commercially
available and in development, the clinical benefits of Sativex(R)
and Epidiolex(R) and the safety profile and commercial potential of
Sativex and Epidiolex. Forward-looking statements involve risks and
uncertainties. Actual events could differ materially from those
projected herein and depend on a number of factors, including
(inter alia), the success of GW's research strategies, the
applicability of the discoveries made therein, the successful and
timely completion of uncertainties related to the regulatory
process, and the acceptance of Sativex, Epidiolex and other
products by consumer and medical professionals. A further list and
description of risks and uncertainties associated with an
investment in GW can be found in GW's filings with the U.S.
Securities and Exchange Commission. Existing and prospective
investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof.
GW undertakes no obligation to update or revise the information
contained in this press release, whether as a result of new
information, future events or circumstances or otherwise.
Enquiries:
GW Pharmaceuticals plc (Today) +44 20 3727 1000
Justin Gover, Chief Executive Officer (Thereafter) + 44 1980 557000
Stephen Schultz, VP Investor Relations +1 917 280 2424 / +1 401 500
(U.S.) 6570
FTI Consulting (Media Enquiries)
Ben Atwell / Simon Conway / John Dineen
(UK) + 44 20 3727 1000
Robert Stanislaro (U.S.) +1 212 850 5657
Trout Group, LLC (U.S. investor relations)
Todd James / Chad Rubin +1 646 378 2900
Peel Hunt LLP (UK NOMAD) + 44 20 7418 8900
James Steel / Clare Terlouw
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBIBDDLBDBGSB
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jun 2024 to Jul 2024
Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Jul 2023 to Jul 2024